Human medicines European public assessment report (EPAR): Exelon, rivastigmine, Dementia,Alzheimer Disease,Parkinson Disease, Date of authorisation: 11/05/1998, Revision: 37, Status: Authorised

Human medicines European public assessment report (EPAR): Rivastigmine Hexal, rivastigmine, Dementia,Alzheimer Disease,Parkinson Disease, Date of authorisation: 11/12/2009, Revision: 10, Status: Authorised

Case Medical Research ◽

10.31525/cmr-1930425 ◽

2019 ◽

Author(s):

Keyword(s):

Alzheimer Disease ◽

Parkinson Disease ◽

Assessment Report ◽

European Public ◽

European Public Assessment Report

Download Full-text

Human medicines European public assessment report (EPAR): Rivastigmine Sandoz, rivastigmine, Dementia,Alzheimer Disease,Parkinson Disease, Date of authorisation: 10/12/2009, Revision: 11, Status: Authorised

Case Medical Research ◽

10.31525/cmr-587204 ◽

2018 ◽

Author(s):

Keyword(s):

Alzheimer Disease ◽

Parkinson Disease ◽

Assessment Report ◽

European Public ◽

European Public Assessment Report

Download Full-text

Human medicines European public assessment report (EPAR): Rivastigmine Sandoz, rivastigmine, Dementia,Alzheimer Disease,Parkinson Disease, Date of authorisation: 10/12/2009, Revision: 11, Status: Authorised

Case Medical Research ◽

10.31525/cmr-559118 ◽

2018 ◽

Author(s):

Keyword(s):

Alzheimer Disease ◽

Parkinson Disease ◽

Assessment Report ◽

European Public ◽

European Public Assessment Report

Download Full-text

Human medicines European public assessment report (EPAR): Prometax, rivastigmine, Alzheimer Disease,Parkinson Disease,Dementia, Date of authorisation: 03/12/1998, Revision: 35, Status: Authorised

Case Medical Research ◽

10.31525/cmr-559115 ◽

2018 ◽

Author(s):

Keyword(s):

Alzheimer Disease ◽

Parkinson Disease ◽

Assessment Report ◽

European Public ◽

European Public Assessment Report

Download Full-text

Human medicines European public assessment report (EPAR): DaTSCAN, ioflupane (123l), Tomography, Emission-Computed, Single-Photon,Lewy Body Disease,Parkinson Disease,Alzheimer Disease, Date of authorisation: 27/07/2000, Revision: 21, Status: Authorised

Case Medical Research ◽

10.31525/cmr-1891668 ◽

2019 ◽

Author(s):

Keyword(s):

Alzheimer Disease ◽

Parkinson Disease ◽

Lewy Body ◽

Single Photon ◽

Lewy Body Disease ◽

Assessment Report ◽

Emission Computed ◽

European Public ◽

European Public Assessment Report

Download Full-text

Human medicines European public assessment report (EPAR): Prometax, rivastigmine, Alzheimer Disease,Parkinson Disease,Dementia, Date of authorisation: 03/12/1998, Revision: 35, Status: Authorised

Case Medical Research ◽

10.31525/cmr-587193 ◽

2018 ◽

Author(s):

Keyword(s):

Alzheimer Disease ◽

Parkinson Disease ◽

Assessment Report ◽

European Public ◽

European Public Assessment Report

Download Full-text

Human medicines European public assessment report (EPAR): Rivastigmine 1 A Pharma, rivastigmine, Alzheimer Disease,Dementia,Parkinson Disease, Date of authorisation: 10/12/2009, Revision: 9, Status: Authorised

Case Medical Research ◽

10.31525/cmr-3996d5 ◽

2018 ◽

Author(s):

Keyword(s):

Alzheimer Disease ◽

Parkinson Disease ◽

Assessment Report ◽

European Public ◽

European Public Assessment Report

Download Full-text

Human medicines European public assessment report (EPAR): Exelon, rivastigmine, Dementia,Alzheimer Disease,Parkinson Disease, Date of authorisation: 11/05/1998, Revision: 37, Status: Authorised

Case Medical Research ◽

10.31525/cmr-3ae9e7 ◽

2018 ◽

Author(s):

Keyword(s):

Alzheimer Disease ◽

Parkinson Disease ◽

Assessment Report ◽

European Public ◽

European Public Assessment Report

Download Full-text

Human medicines European public assessment report (EPAR): Memantine Mylan, memantine, Alzheimer Disease, Date of authorisation: 21/04/2013, Revision: 4, Status: Authorised

Case Medical Research ◽

10.31525/cmr-3996cc ◽

2018 ◽

Author(s):

Keyword(s):

Alzheimer Disease ◽

Assessment Report ◽

European Public ◽

European Public Assessment Report

Download Full-text

Human medicines European public assessment report (EPAR): Pramipexole Teva, pramipexole, Parkinson Disease, Date of authorisation: 18/12/2008, Revision: 19, Status: Authorised

Case Medical Research ◽

10.31525/cmr-1e4edd3 ◽

2019 ◽

Author(s):

Keyword(s):

Parkinson Disease ◽

Assessment Report ◽

European Public ◽

European Public Assessment Report

Download Full-text